Format

Send to:

Choose Destination
See comment in PubMed Commons below
Genes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.

Author information

  • 1Department of Biochemistry and Molecular Biology, University of California at San Francisco, San Francisco, California 94143, USA.

Abstract

Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases. The median survival of this group of patients after diagnosis is ∼1 yr. Here we show that the levels of H3K27 di- and trimethylation (H3K27me2 and H3K27me3) are reduced globally in H3.3K27M patient samples due to the expression of the H3.3K27M mutant allele. Remarkably, we also observed that H3K27me3 and Ezh2 (the catalytic subunit of H3K27 methyltransferase) at chromatin are dramatically increased locally at hundreds of gene loci in H3.3K27M patient cells. Moreover, the gain of H3K27me3 and Ezh2 at gene promoters alters the expression of genes that are associated with various cancer pathways. These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.

KEYWORDS:

H3.3K27M; H3K27 methylation; PRC2; gliomas; pediatric

PMID:
23603901
[PubMed - indexed for MEDLINE]
PMCID:
PMC3656328
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk